

Ahead of the curve

*Leadership in our focus areas
for medicines that matter*



Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”).

This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

Thank you, Enno! Welcome Laetitia!

The Management Team



**Werner
Lanthaler**
CEO



**Laetitia
Rouxel**
CFO
(from April 2023)



**Craig
Johnstone**
COO



Matthias Evers
CBO



**Enno
Spillner**
CFO
(till March 2023)



**Cord
Dohrmann**
CSO



“I am excited to join Evotec at this stage of its impressive journey. Helping to shape the organisation to foster resilience and agility as well as improving its sustainable profitable growth is what I want to contribute.”

Laetitia Rouxel
Chief Financial Officer
(as of 1 April)


Agenda

Highlights

Scientific and operational performance 2022

Financial performance 2022

Outlook and Guidance 2023



Convergence, right tools, technologies & disease understanding

Evotec advancements against industry trends

Selected industry trends

Evolution of targeted **protein degradation**

First use of **CRISPR** nucleases in gene editing

Discovery with **iPSCs**

Establishing of **A.I. in medicine**


First **gene therapy** trials launched

mRNA vaccine technology used

Completion of the **Human Genome Project**

Multi-omics gaining momentum

Personalized medicine



AHEAD OF THE CURVE

Evotec selected advancements

Paradigm shift in biologics with A.I./M.L.-based discovery to continuous manufacturing

E.RNA as druggable molecules

Unique **molecular patient databases** **E.MPD**

Targeted protein degradation
Drugging the undruggable with molecular glues

True Precision medicine with **PanOmics, PanHunter**

End-to-end platform for **iPSC-based cell therapy**


Industrialising **iPSC** technology for discovery

Enhancing **drug discovery** with A.I./M.L.

Cornerstones laid for development of **multi-omics technology in discovery and diagnostics**

Strong demand in all lanes

Highlights & lowlights 2022



Highlights

- Significant progress in major partnerships with Bristol Myers Squibb (BMS); targeted protein degradation alliance extended for additional 8 years; important milestones achieved in iPSC-neuro strategic collaboration
- Eight-year expansion and extension of iPSC-neuro alliance (after period-end)
- iPSC-based beta cell replacement therapy alliance with Sernova to advance a functional cure for diabetes
- Multiple new strategic partnerships in e.g., metabolic diseases, ophthalmology, dermatology, oncology ...
- Just – Evotec Biologics: New collaborations laying foundation for growth in 2023 and beyond; building of 2nd J.POD Toulouse according to plan
- Acquisition of cell therapy manufacturing facility (Evotec Modena) and clinical & commercial manufacturing platform for small molecule therapeutics (Evotec DS in Halle)
- World-leading in data-driven precision medicine platforms; Commercial launch of unique multi-omics data analysis platform PanHunter
- Launch and major expansion of translational molecular patient databases E.MPD
- Collaboration with Janssen to develop first-in-class targeted immune-based therapies for oncology (after period-end)
- European Investment Bank (EIB) has granted an unsecured loan facility of € 150 m (after period-end)

Lowlights

- Bayer discontinued development of selected women's health projects (P2X3)
- Increased costs for energy and materials and overall high inflation
- Slower than anticipated revenue ramp-up from J.POD biologics manufacturing

Another year with strong double-digit growth

Results versus previous year and guidance

	FY 2021 results	FY 2022 results ⁴⁾	Yoy growth like-for-like / at constant fx-rates ¹⁾	Guidance	
Group revenues (at constant fx-rates ¹⁾)	€ 618.0 m	€ 748.4 m (€ 707.7 m)	21% / 15%	€ 715 – 735 m (€ 690 – 710 m)	✓
Unpartnered R&D²⁾	€ 58.1 m	€ 70.1 m	21%	€ 70 – 80 m	✓
Adjusted Group EBITDA³⁾ (at constant fx-rates ¹⁾)	€ 107.3 m	€ 104.1 m (€ 81.1 m)	(3)% / (24)%	€ 105 – 120 m (€ 85 – 100 m)	✓

Strong growth and improving profitability towards Action Plan 2025


Guidance 2023

	Guidance 2023	YE 2022 ³⁾	Implied growth at midpoint
Group revenues (at constant fx-rates ¹⁾)	€ 820 – 840 m (€ 835 – 855 m)	€ 751.4 m	>10%
Unpartnered R&D²⁾	€ 70 – 80 m	€ 70.2 m	At least stable
Adjusted EBITDA (at constant fx-rates ¹⁾)	€ 115 – 130 m (€ 125 – 140 m)	€ 101.7 m	>20% (>30%)

Approx. € 250 m continued investment programme for enabling and supporting growth (e.g., capacity expansion in biologics manufacturing, safety testing, iPSC, E.MPD...)

Action Plan 2025 on track

Action Plans in numbers



¹⁾ Including equity investments

²⁾ Does not include EVT equity investments


Building a massive long-term royalty pool

Selected KPIs




>130
Co-owned pipeline assets

18
Clinical stage



>€ 15 bn
Potential partnership milestones

8 -10 %
Average royalty rate




Agenda

Highlights

Scientific and operational performance 2022

Financial performance 2022

Outlook and Guidance 2023



Our four Focus Areas

Overview

PanOmics

Deep disease understanding for effective therapies




iPSC-based Cell Therapies

“Off-the-shelf” cell therapies based on induced-pluripotent stem cells



Just – Evotec Biologics

From Artificial Intelligence (“A.I.”) to continuous manufacturing for better access to biologics



End-to-end Shared R&D


Integrated business-to-business platform for increased probability of success from target to patient




Together for medicines that matter

Fully integrated in discovery, development & manufacturing

Illustrative functional capabilities along the value chain





**PanOmics-driven drug
discovery for better
disease understanding**

PanOmics is already a success – much more to come!

Examples of PanOmics-driven collaborations

PanOmics data generation



PanHunter data analytics



Revenues of > € 150 m

> 20 collaborations

> 50 programmes

Largest deal in one of the most competitive fields in the industry

Targeted protein degradation alliance with BMS signed in 2022




Developing a pipeline of breakthrough therapies based on molecular glue degraders

- 8-year extension and significant expansion of original agreement signed in 2018
- Collaboration leverages Evotec's PanOmics and PanHunter platforms including A.I./M.L. capabilities
- Upfront payment of \$ 200 m
- Performance-based and programme-based payments of \$ 75 m announced in March 2023
- Total deal value of up to € 5 bn; milestone-based payments
- Additionally, tiered royalties for each program

Strategic expansion of a highly successful partnership

Leveraging precision medicine platform **in neurodegeneration**



Next step

- 8-year extension and significant expansion of original agreement from 2016
- Development of novel therapies
- US\$ 50 m upfront¹⁾; deal value > US\$ 4 bn; tiered double-digit royalties
- Collaboration leverages proprietary platforms such as E.iPSC, PanOmics and PanHunter



“We look forward to continuing our drug discovery research into key mechanisms in neurodegeneration and delivering potential therapeutic candidates for patients who are suffering from these devastating diseases.”

Prof. Richard Hargreaves, PhD

SVP, Neuroscience Thematic Research Center – Bristol Myers Squibb



“The combination of our industrialised iPSC disease models, -omics at scale and AI/ML- based analytics will accelerate the discovery and translation from bench to bedside.”



Dr Cord Dohrmann

CSO Evotec

Aging is driving incidence rates of neurodegenerative diseases

Societal burden of Central Nervous System related diseases

% of people aged 60+ by region (2020 vs. 2050e)



Need for paradigm shift


- Limited understanding of the underlying molecular mechanisms
- Second leading cause of death after cardiovascular disease
- Patient derived iPSC models more predictive than traditional animal models
- Global neurodegenerative disease market (US\$ 40 bn in 2021) expected to reach > US\$ 53 bn by 2030

Increasing PoS with differentiated precision drug discovery

Industrialised iPSC disease models and Omics-platforms at scale

Wealth of „inputs“

Tissues,
primary cells
and E.iPSCs



E.MPD

Real
world data



Panhunter A.I./M.L. driven data analytics

PanOmics Industrialised Omics data generation

„Study disease mechanisms“

Omics-based Molecular Patient Database

„Reversion of disease signatures“


Novel, validated targets

„Confirmation in human disease models“

iPSC co-cultures

Program pipeline


Modality
agnostic



Relevant
biomarkers




Right
patients




High-value dealmaking underlines big pharma CNS ambitions

Analysis of selected deals in the last years

Diseases of the central nervous system continue to catalyse dealmaking as companies search for new therapies to tackle some major unmet medical needs.



● Size of bubble denotes breadth of pipeline




STEM CELLS

**iPSCs – Cell Therapy based
on induced-pluripotent
stem cells**


Off-the-shelf approach will revolutionise cell therapy applications

Benefit of manufacturing process for iPSC-based therapeutics


Autologous



Allogeneic donor-derived



Allogeneic iPSC-derived



iPSC-based therapeutics

- **Reduced manufacturing complexity** – Patient is not part of manufacturing process
- Unlimited starting material
- Versatile & high-fidelity gene editing
- Consistent quality of final product
- On demand product available to patients
- Broad applicability: Suitable for multiple cell types & disease areas

“The product is the process”
















Cell therapy manufacturing facility with acquisition of Rigenerand now Evotec Modena



- Founded in 2009 as spin-off of the University of Modena and Reggio Emilia
- Scientific founder Prof. Massimo Dominici one of the pioneers in clinical cell therapy
- State-of-the art GMP facility (5 clean rooms, 1,200 m²) with room for expansion
- cGMP facility accredited by Italian Authority for manufacturing of cell therapies
- Experienced to manufacture complex cell therapies including pre-GMP optimization
- Experience with MSCs, TILs, CAR-T, dendritic cells and exosomes
- Tech transfer for manufacturing of iPSC-based therapeutics on-going




A comprehensive portfolio of early iPSC-based cell therapy assets

Off-the shelf cell therapy programmes


Field	Program/Project	Disease area	Protocol development	Pre-clinical research	Pre-clinical development	IND / Phase I
Anti-tumour therapy	iNK	Oncology		 ¹⁾		
	iM	Oncology				
	$\gamma\delta$ iT	Pharma partner Oncology		Undisclosed		
	$\alpha\beta$ iT	Oncology				
Diabetes	E.iBeta (Device)	 Diabetes				
	E.iBeta (Engineered)	Diabetes				
Other	iCM	Heart failure				
	iRPE, iPR	Ophthalmology				
	...					

iPSC-derived cell types

- iNK Natural killer cells
- iT $\alpha\beta$ and $\gamma\delta$ T cells
- iM Macrophages
- iBeta Pancreatic islets
- iCM Cardiomyocytes
- iRPE Retinal pigment epithelium cells
- iPR Photoreceptors

 Unpartnered, open for new business opportunities  /  Partnered

Just – Evotec Biologics Continuous manufacturing for better access to biologics



Our mission is to contribute to much better access to biologics

Access for all



7,000

underserved rare indications that could be addressed with biologics

Underserved indications



70%

higher prices for antibodies vs. small molecules in the US alone

Underserved populations



6 bn

without access to biologics based on geography

Underserved regions¹⁾



12 months


to first Ab therapy in COVID

Communicable diseases & pandemics²⁾

First strong quarter, many more to come ...

Key achievements 2022

Closed Sales, Sales in € m



Key progress



Secured and initiated new anti-Plague mAb development programme




First commercial process development

Undisclosed biosimilar partner

Pilot project ongoing

Revenues and EBITDA by quarter in 2022, in € m



J.POD – commercial biologics manufacturing stepping up

Progress and status



Aerial view of new location in Redmond, Washington, US



View of coming J.POD® in Toulouse (architectural rendering)¹⁾



Signature ceremony of EIB loan at Evotec's Campus Curie in Toulouse

- Start of operations fully on track, e.g., US Department of Defense (DoD), ...
- Number of partnerships and volume of sales order book already tripled 2022 versus 2021
- Ground-breaking for second new biologics facility J.POD Toulouse in September 2022
- EIB-loan facility of € 150 m to support new J.POD facility in Toulouse as well as R&D activities and equity investments (after period-end, approx. 50% of loan dedicated to J.POD)



**End-to-End Shared R&D –
Integrated B2B platform for
increased probability of
success**

Well-balanced global customer mix further improving

Sharing as basis for success




>800

Partners

~38%

Revenue share with TOP 10 partners (2021: 42%)




92%

repeat business

118


No. of partners with > € 1 m revenues (+22%)



Comprehensive integrated research and development

Major developments (selection) in End-to-End shared R&D


Ent-to-End Shared R&D business mix



+18%

again faster than market

Global R&D Outsourcing market by segment²⁾



- € 495.4 m¹⁾ revenue in end-to-end shared R&D
- >5 new and/or extended integrated drug discovery agreements centered on A.I./M.L.-driven small molecule design capabilities
- 10 performance-based milestones and success payments
- Complement API Capabilities with acquisition of an EU GMP certified facility in Halle (Evotec DS) with clear path to the market for rare diseases
- Strong performance of DMPK / ADME-tox testing; Cyprotex capacity expansion to meet strong demand


Agenda

Highlights

Scientific and operational performance 2022

Financial performance 2022

Outlook and Guidance 2023



Very strong progress in a challenging year

Condensed preliminary income statement 2022 – Evotec SE and subsidiaries

in € m¹⁾

	2022	2022 Guidance	2021	Change	Comment
Revenues	751.4	715 – 735	618.0	22%	Strong base business
• <i>of which Just – Evotec Biologics (JEB)</i>	<i>51.3</i>	<i>–</i>	<i>52.9</i>	<i>(3)%</i>	<i>Improved mix</i>
Gross margin	23.2%	–	24.5%	(130) base pts.	JEB, less MS & inflation impact
• <i>Gross margin excl. JEB</i>	<i>31.1%</i>	<i>–</i>	<i>28.4%</i>	<i>270 base pts.</i>	<i>Strong partner mix</i>
Unpartnered R&D expense	70.2	70 – 80	58.1	21%	As planned
Adjusted Group EBITDA²⁾	101.7	–	107.3	(6)%	Ambitious goal reached ⁴⁾
Adjusted Group EBITDA excl. M&A ^{2,3)}	104.1	105 – 120	107.3	(4)%	Strong
Adjusted Group EBITDA excl. JEB²⁾	138.3	–	115.2	20%	Very strong
Scope 1 & 2 emissions (tons CO ₂ e)	38,549	–	39,351	(2)%	Sustainable growth

¹⁾ Differences may occur due to rounding


²⁾ Adjusted EBITDA excludes changes of contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

³⁾ Excluding effects related acquisitions of Rigenrand (Medolla, I) and Central Glass (Halle/Westphalia, GER); as guided in March 2022 4) incl. M&A as outlined in 9M 2022 results call on 9 November 2022


High-quality gross margin in base business

Revenues & Gross margin overview – Evotec SE and subsidiaries

Revenues from contracts with customers (in € m)




Gross margin (in %)



- 15% organic growth of Group revenues, at constant fx-rates
- fx tailwind: 6.6% / M&A: 0.5%
- Group revenues € 700.1 m – excluding Just – Evotec Biologics, up 24%
- Base revenues up 30%
- Group gross margin of 31.1% excluding Just – Evotec Biologics up 270 base points despite significantly higher energy and material costs and lower contribution from milestones

Q4 2022 - The anticipated strong finish to the year

Adj. EBITDA overview – Evotec SE and subsidiaries incl./excl. Just – Evotec Biologics



- Visible contribution from milestones, upfronts, licenses & royalties
 - BMS Neuro, Janssen, others
- Excellent base business with strong operating leverage
- First strong quarter of Just – Evotec Biologics
 - Goal of tripling Q3 revenues achieved in Q4
 - Strong operating leverage
 - First small contribution from royalties
 - Results to remain volatile in 2023

Q4 2022 – The strongest quarter in 30-year history

Condensed income statement Q4 2022 – Evotec SE and subsidiaries

in € m¹⁾

	Q4 2022	Q4 2021	Change
Revenues	240.7	187.1	29%
<i>Gross margin</i>	34.3%	27.8%	650bp
• R&D expenses	(21.3)	(18.7)	14%
• SG&A expenses	(46.3)	(34.4)	35%
• Impairment of intangible assets & goodwill	–	–	–
• Other op. income (expenses), net	22.9	16.0	43%
Operating income	37.7	14.9	152%
Adjusted Group EBITDA²⁾	57.1	37.2	53%
Net income	(27.2)	(31.5)	(14%)

- 29% revenue growth versus strong comparable base
- Substantially improved gross margin due to
 - favourable mix of milestones upfronts & license payments (albeit below last year)
 - small royalties from SK Bioscience
 - very profitable base business
 - visible improvement of Just – Evotec Biologics
- Record EBITDA with strong growth despite cost inflation in 2022 and higher contribution from milestones in previous year

Strong balance sheet as very solid base for future growth

Balance sheet and Cash-flow items – 31 Dec. 2022 vs. 31 Dec. 2021 – Evotec SE & subsidiaries

Balance sheet total
in € m

~~2,235.2~~ **2,257.2**

Equity ratio
in %

~~61.6~~ **52.6**

Operating Cash-flow
in € m

~~122.2~~ **203.0**

Net Debt ratio
x adjusted EBITDA

~~(3.2)~~ **(2.0)**

Liquidity position
in € m

~~858.2~~ **718.5**

Capex, Equity investments & Acquisitions
in € m

~~147.4~~ **265.2**


Agenda

Highlights

Scientific and operational performance 2022


Financial performance 2022

Outlook and Guidance 2023




Our mid-term aspirations are “... just the beginning”

2020-2025e Key Performance Indicator goals (as introduced on 20 April 2021)



Revenues
in € m



Adjusted EBITDA¹⁾
in € m



Unpartnered R&D
in € m



Co-owned projects²⁾



¹⁾ before significant royalties

²⁾ incl. Equity participations


Sustainable growth enabled by strong culture, values & people

Innovation – Entrepreneurship – Collaboration



33%
Share of PhDs


91
Nationalities



Gender	Percentage
Men	46%
Women	54%

31%
Women in Senior
Management

38
Average age



Ca. 500 net new talents
planned for 2023

Keeping the promise

ESG & Sustainability – Measures taken in 2022

• Environment


- Scope 1 & 2 and supplier related Scope 3 SBTi near-term targets set and submitted
- Installation of first air source heat pump (Building B95 in Abingdon)
- Campus Curie connected to renewable energy heating network *Toulouse Energie Durable (TED)*
- Reduction of Scope 1 & 2 emissions by 2% even before SBTi targets in place

• Social

- Expansion of investments in disease areas under UN SDG3
- Launch of Aurobac Therapeutics, JV with Boehringer Ingelheim and bioMérieux; Targeting Antimicrobial Resistance (“AMR”) with next generation antimicrobials and diagnostics
- Diversity Month and Pride Month; Joined Proud Science Alliance; Evotec @ London Pride

• Governance

- Governance roadshow of Chairwoman of Supervisory Board
- Formation of ESG Committee within the Supervisory Board
- Scoping and prioritisation of ESG projects in 2023
- Expansion of ESG Team
- Implementation of Supplier Code of Conduct




Our promise

ESG Goals 2023

Approve and implement the SBTi initiative action plan at all Evotec sites and invest one percent of 2022 revenues to achieve SBTi targets.


Conduct engagement survey by mid 2023.
Define and communicate a management plan for 2024 and beyond based on results of engagement survey.

Engage sustainability champions at each site to create governance structures fostering environmental and social goals as well as site specific sustainability projects.



Executing to accelerate growth along Action Plan 2025

Selected major newsflow 2023



PanOmics	<ul style="list-style-type: none"> • New strategic partnerships and expansions of co-owned alliances • New clinical trial initiations • Significant progress of later stage co-owned pipeline 	✓
iPSCs	<ul style="list-style-type: none"> • New strategic partnerships • Progression of partnered cell therapy assets, e.g., Sernova • Expansion of internal portfolio of cell therapy assets 	✓ ✓
Just – Evotec Biologics	<ul style="list-style-type: none"> • Significant expansion of order book for J.POD Redmond, WA (US) • Progression of construction J.POD Toulouse, France (EU)¹⁾ • Evaluation of global network of J.PODs 	
End-to-End Shared R&D	<ul style="list-style-type: none"> • Undisrupted growth trend versus 2022 in line with AP 2025 • Integration of Evotec DS Germany 	
Group	<ul style="list-style-type: none"> • Submission of science-based targets aligned with 1.5°C goal • Highly impactful contribution to UN SDG 3²⁾ • Spin-Offs and investments along Building Blocks of AP 2025 	✓ ✓

¹⁾  This project benefits from French government funding as part of the Investments for the future Programme (programme d'investissements d'avenir in French) and is also supported economically by the Occitanie Region and Toulouse Métropole.

²⁾ UN Sustainable Development Goal 3: Improve health and well-being with main targets for us on cardiovascular diseases, diabetes, women's health, fight against infectious diseases and pandemic preparedness

Upcoming important dates


Financial calendar 2023

Quarterly Statement Q1 2022	10 May 2023
1st Capital Markets Day 2023 (virtual)	5 June 2023
Virtual Annual General Meeting 2023	20 June 2023
Half-year 2023 Interim Report	09 August 2023
Quarterly Statement 9M 2023	08 November 2023
2nd Capital Markets Day 2023	15 November 2023



Full annual report and sustainability report 2022
available for download on 25 April 2023

QUESTIONS
AND ANSWERS



Appendix

Revenues up

Segment information 2022 – Evotec SE and subsidiaries

in € m¹⁾

	EVT Execute	EVT Innovate	Inter- segment elimination	Evotec Group
Revenues	735.6	204.7	(188.9)	751.4
<i>Gross margin</i>	17.7%	28.9%	–	23.2%
• R&D expenses	(5.3)	(86.3)	15.0	(76.6)
• SG&A expenses	(125.3)	(30.9)	–	(156.2)
• Impairment of intangible assets & goodwill	–	–	–	–
• Other op. income (expenses), net	33.2	46.4	–	79.6
Operating income	32.5	(11.7)	–	20.9
Adjusted Group EBITDA²⁾	108.3	(6.6)	–	101.7

- Accelerated growth in fourth quarter
- EVT Execute total revenue growth up 21%; Growth excluding Just – Evotec Biologics plus 23%
- EVT Innovate revenues up 39%, due to expansion of highly profitable precision medicine collaborations; gross margin increase by 380 bp despite lower milestone contribution
- Adjusted EBITDA within lower end of guidance as communicated in November based on **strongest quarter in company history**


Business-to-business model in Biotech is highly scalable

Value creation pillars

	IP partnering ¹⁾ / Pipeline of co-owned assets	Partner owns IP
Value Creation Model	<ul style="list-style-type: none"> • Fee for Service / FTE rates • Upfront payments, milestones, licenses, royalties • Equity investments 	<ul style="list-style-type: none"> • Fee for Service / FTE rates • Success payments • Price per amount manufactured
Focus areas	<div style="display: flex; justify-content: space-around;"> <div style="border: 1px solid black; padding: 5px; width: 20%;">PanOmics</div> <div style="border: 1px solid black; padding: 5px; width: 20%;">iPSCs</div> <div style="border: 1px solid black; padding: 5px; width: 60%;">End-to-End Shared R&D</div> </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;">Just – Evotec Biologics</div>	

Strong Sustainability Governance in place

Supervisory Board assumes responsibility for sustainability



Growing fast *and* responsibly

SBTi¹⁾ targets language

*„Evotec SE commits to **reduce absolute Scope 1 and 2 GHG emissions 50% by 2032** from a 2021 base year. Evotec SE also commits to increase annual sourcing of **renewable electricity** from 25% in base year to **100% by 2026**. Evotec SE commits to **reduce Scope 3 GHG** from purchased goods and services and capital goods **72% per revenue** over the same period. Evotec also commits that **80% of its suppliers** by emissions covering purchased goods and services and capital goods **will have science-based targets by 2027.**”*


Science-based targets balancing fast growth and responsibility for the planet

- RE100 target year 2026 earlier than outlined in Paris agreement (*LTI goal 2023*)
- 50% reduction of Scope 1 and 2 emissions by 2032 aligned, despite disproportionately faster growth than industry average
- Evotec will act as multiplier with its supplier engagement program



EVOequity complements co-owning strategy

Operational VC model – diversified portfolio with multiple shots on goal



At Equity Holding (≥20%) or significant influence



Minority Shareholdings (<20%)




BRIDGES



Centres of excellence to discover, develop & manufacture

Together for medicines that matter with ~5,000 people at 17 sites



“Evotec inside”

Pipeline of co-owned assets

Selected pipeline events within next 12-24 months

- Phase III & registration (CHN) JingXin in insomnia (EVT201)
- Phase II data with Bayer in B1 (BAY2395840)
- Phase II initiation with Bayer in Gynaecology (BAY2395840)
- Phase I data in Chikungunya virus (EVT894)
- Phase I data with BMS in CNS (EVT8683)
- Phase I data with Kazia in Oncology (EVT801)
- Phase Ib / II initiation of Exscientia in Oncology (EXS21546)
- Phase I initiation in HBV (EVT075)
- Phase I initiation with Bayer in Kidney
- Phase I initiations with Kidney diseases with other partners
- Phase I initiation with BMS in CNS
- Phase I initiation with BMS in Oncology
- Phase I initiation with Sernova in Diabetes
- Progress of multiple co-owned equity companies (not disclosed) (e.g. Topas, ...)

	Molecule	Therapeutic Area / Indication	Partner	Discovery	Pre-clinical	Phase I	Phase II	Phase III	Approved
Clinical	SKYCovione	COVID-19	SK bioscience						
	EVT201	Insomnia (GABA-A)	京新药业						
	BAY2395840	Multiple Indications (B1)	Bayer						
	CT7001	Oncology (CDK7)	Carrick						
	XP-105	Oncology (mTORC1/2)	EXONIC						
	TPM502	Celiac Disease	Topas Therapeutics						
	EXS21546	Oncology (various programmes)	Exscientia						
	BAY2328065	Gynaecology	Bayer						
	EVT401	Immunology & Inflammation (P2X7)	康恩贝集团 CONBA GROUP						
	CNTX 6016	Pain (CB2)	CENTREKIN						
	EVT894	Chikungunya (Antibody)	NIH sanofi						
	Not Disclosed	Neuroscience & Pain	n.a.						
	Not Disclosed	Neuroscience & Pain	n.a.						
	EVT801	Oncology (VEGFR3)	KAZIA						
	EVT8683	Neurodegeneration (eIF2b activator)	Bristol Myers Squibb						
	TPM203	Pemphigus Vulgaris (ND)	Topas Therapeutics						
	CT7001	Oncology (CDK7)	Carrick						
CT7001	Oncology (CDK7)	Carrick							
Pre-clinical	APN411	Oncology – Immunotherapy	sanofi APEIRON						
	BAYxxxx	Nephrology (not disclosed)	Bayer						
	QRB001	Metabolic – Diabetes (not disclosed)	QRbeta Sernova						
	EVT075	HBV	n.a.						
	Not disclosed	Various programmes	Bristol Myers Squibb						
EVTxxxx	CNS, Metabolic, Pain, ...	>25 further programmes							
Discovery	EVTxxx CKD, oncology, immunology ... > 90 further programmes								

The growing “iceberg” of first & best-in-class treatment options

>250 projects including EVOequity and BRIDGEs: ~190 in partnerships, >60 internal R&D

		Neuroscience & Pain				Oncology				Metabolic Diseases				Inflammation & Immunology ¹⁾			Communicable diseases																																																																																																																																																																																																																																																																																																																																				
Approved																		COVID-19																																																																																																																																																																																																																																																																																																																																			
Registration		Insomnia																																																																																																																																																																																																																																																																																																																																																			
Clinical	Ph3																	Breast Cancer																																																																																																																																																																																																																																																																																																																																			
	Ph2	DNP																	A2A																	Carrick																	Topas																																																																																																																																																																																																																																																																																																
	Ph1	Pain																																	Carrick																	Endo																	Topas																																																																																																																																																																																																																																																																																
Preclinical		ND																	Exscientia																	EVT801																	Carrick																	Endo																	Topas	CHIK-V																																																																																																																																																																																																																																																													
Discovery		ND																	Exscientia																	Exscientia																	Carrick																	ND																	Encaps iB																	EVT																	ND																	Fibrocor																	HBV																	COVID-19																	Noso-502																	Forge																																																																																																																																							
Discovery	LO	ND																	Facio																	IO																	Onco																	Onco																	Autobahn																	Eternigen																	Exscientia																	LAB150																	QRbeta																	EVT																	NephThera																	Topas																	LAB282																	Cystobac-tamid																	Malaria																																																																																				
		ND																	Argobio																	Onco																	Onco																	Onco																	EVT																	Immunitas																	ND																	EVT																	LAB282																	Exscientia																	Breakpoint																	Tribe CarbX																	Forge	Rescorci-nomycin																																																																																																																					
		ND																	LAB282																	Onco																	EVT																	Autobahn																	DarkBlue																	ND																	EVT																	Exscientia																	Celmatix																	Fibrocor																																																																																																																																																																									
	H2L	ND																	LAB282																	Onco																	EVT																	Breakpoint																	LAB282																	EVT																	EVT																	Blacksmith																	Bayer																	ND																	Blacksmith																	AP series																																																																																																																																							
		ND																	LAB282																	EVT																	EVT																	Carrick																	Blacksmith																	Danube Labs																	EVT																	EVT																	NephThera																	Bayer																	ND																	Fibrocor																	LAB282																	Forge	NP whole cell																																																																																																				
	AD/Scr	ND																																	EVT																																	EVT																	EVT																	EVT																	EVT																	EVT																	EVT																	HBV-HBx																	HBV-RNA																	PP HTS																																																																																																																																									
		ND																	EVT																	Autobahn																	EVT/MF																	Immunitas																	ND																	EVT																	EVT																	EVT																	HBV-HBc																	Whole cell HTS 2																																																																																																																																																																									
		ND																	EVT																	Cajal Neuro																	EVT/MF																	Ananke																	Quantro																	ND																	EVT																	EVT																	ND																	Celmatix																	EBV																	NIPAH																	eAMR																	Whole cell HTS 1																																																																																																					
		ND																	EVT																	Facio																	EVT/TMF																	Autobahn																	BELAB1407																	ND																	ND																	EVT																	EVT																	ND																	CureXsys																	Flu1																	NIPAH																	Staph persist.																	Pdt screen																																																																																				
		ND																	EVT																	Exscientia																	LAB282																	Onco																	ND																	EVT																	Argobio																	LAB282																	ND																	ND																	EVT																	LAB150																	Flu2																	Exscientia																	HDT																	Forge	Forge																																																																		
TI/TV	ND																	EVT																	CureXsys																	LAB150																	Onco																	ND																	EVT																	OxVax																	LAB150																	ND																	Fibrosis																	EVT																	NephThera																	EVT																	Fibrocor																	LAB282																	BKV																	LAB282																	VMM																	Exscientia																	TB Pat DB

■ Partnered Pipeline
 ■ Unpartnered Pipeline
 ■ Equity Pipeline
 ■ Bridges Pipeline

¹⁾ Also includes Women’s Health, Respiratory projects
 The Equity Pipeline does not contain programs from EVT/partners that are not publicly disclosed
 Status as of 31.12.2022

Abbreviations:
 TI/TV = Target identification/Target validation, Scr = Screen,
 AD = Assay development, H2L = Hit to Lead, LO = Lead optimisation



#RESEARCHNEVERSTOPS

Your contact:

Volker Braun
SVP Head of Global Investor Relations & ESG

+49 (0) 40 560 81-775
+49 (0) 151 1940 5058 (m)
volker.braun@evotec.com
